Cite
Response to Crizotinib in a Patient with MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib.
MLA
Stein, Mark N., et al. “Response to Crizotinib in a Patient with MET-Mutant Papillary Renal Cell Cancer After Progression on Tivantinib.” European Urology, vol. 67, no. 2, Feb. 2015, pp. 353–54. EBSCOhost, https://doi.org/10.1016/j.eururo.2014.10.012.
APA
Stein, M. N., Hirshfield, K. M., Zhong, H., Singer, E. A., Ali, S. M., & Ganesan, S. (2015). Response to Crizotinib in a Patient with MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib. European Urology, 67(2), 353–354. https://doi.org/10.1016/j.eururo.2014.10.012
Chicago
Stein, Mark N., Kim M. Hirshfield, Hua Zhong, Eric A. Singer, Siraj M. Ali, and Shridar Ganesan. 2015. “Response to Crizotinib in a Patient with MET-Mutant Papillary Renal Cell Cancer After Progression on Tivantinib.” European Urology 67 (2): 353–54. doi:10.1016/j.eururo.2014.10.012.